Table 2.

Univariate relations to DFS and OS

DFSOS
HR (95% CI)*PHR (95% CI)*P
Age≥60 vs <60 y0.50 (0.14-1.81)0.290.85 (0.26-2.8)0.79
GenderMale vs female26.5 (0.05-10,000)0.3131.8 (0.06-10,000)0.28
SitePharynx, palate vs base of tongue, tonsil1.63 (0.21-12.6)0.645.0 (1.5-23.7)0.043
T stage3,4 vs 1,24.36 (1.46-13.0)0.0082.60 (0.82-8.3)0.11
N stage2,3 vs 0,12.05 (0.45-9.2)0.351.03 (0.28-3.8)0.97
StageIV vs II,III4.05 (0.53-31.1)0.181.53 (0.33-7.0)0.58
Smoking≥1 vs <1 pack-year2.34 (0.72-7.6)0.162.03 (0.61-6.8)0.25
Excessive alcohol useYes vs no3.71 (1.24-11.1)0.0192.84 (0.90-9.0)0.075
ChemotherapyHigh-dose vs weekly0.81 (0.18-3.67)0.791.41 (0.38-5.3)0.61
HPV16Positive vs negative0.21 (0.069-0.61)0.0050.40 (0.13-1.25)0.11
p16Positive vs negative0.22 (0.073-0.65)0.0060.42 (0.12-1.4)0.15
Bcl2Positive vs negative3.25 (1.06-10.0)0.0394.09 (1.23-13.6)0.022
BclXLPositive vs negative1.16 (0.39-3.45)0.791.87 (0.59-5.9)0.29
  • *CI by Cox proportional hazard analysis.

  • Wald test.